What's Happening?
Roche has announced promising results from two phase 3 trials of its oral BTK inhibitor, fenebrutinib, which could become the first drug in its class approved for multiple sclerosis (MS). The FENhance 1 and 2 studies demonstrated significant reductions
in relapses and brain lesions in patients with relapsing multiple sclerosis (RMS) compared to the standard treatment, Sanofi's Aubagio. The trials reported a 51.1% and 58.5% drop in the annualized relapse rate, respectively. Despite an imbalance in fatalities between the treatment and control groups, Roche clarified that these deaths were unrelated to the drug. The company plans to file for approval of fenebrutinib for both RMS and primary progressive multiple sclerosis (PPMS), projecting potential sales of $5 billion annually.
Why It's Important?
The development of fenebrutinib is significant as it offers a potential new high-efficacy oral treatment for MS, a condition that affects millions worldwide. Current treatments often involve injections or infusions, so an effective oral option could improve patient compliance and quality of life. The drug's ability to significantly reduce relapses and brain lesions could alter the treatment landscape for MS, providing a more convenient and potentially more effective option for patients. Additionally, the success of fenebrutinib could drive further research and development in BTK inhibitors, potentially leading to breakthroughs in treating other neurological conditions.
What's Next?
Roche is preparing to file for regulatory approval of fenebrutinib for both RMS and PPMS. If approved, it would be the first high-efficacy oral treatment for these forms of MS, potentially setting a new standard in MS care. The company is also planning to seek approval for its anti-IL-6 antibody, Enspryng, for treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), following positive phase 3 trial results. These developments could lead to new treatment options for patients with autoimmune diseases affecting the nervous system.
